Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill

Rani Therapeutics Holdings, Inc.

Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.
Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.
Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.
Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.